



# VIRTUAL UK ONCOLOGY FORUM 2021

## 21st and 22nd October 2021

## Final Agenda

To receive a CPD certificate you must attend:

At least 3 clinical sessions (eg Lung, Melanoma, Radiotherapy) etc.

Both keynote lectures

The Covid/Cancer discussion

The platform will monitor individual attendees “conference foot-print”. The secretariat is duty bound to ensure that all healthcare professionals attend the sessions, to be awarded CPD. Programme evaluation is compulsory, certificates will ONLY be awarded if all evaluations are completed.

**CME accreditation is NOT awarded for Industry Symposia.**

Industry Symposia will **NOT** be run parallel to the UKOF programme.

# DAY ONE – THURSDAY 21<sup>ST</sup> OCTOBER 2021

TIME	SUBJECT	
08:30hrs ~ 10:30hrs	<b>UKONS – Sexual Health and Cancer 2 - all registered OF21 HCPs Welcome</b>	
	08:30hrs ~ 08:35hrs	Welcome and introduction to the UKONS session Kay Bell, UKONS Board member
	08:35hrs ~ 08:45hrs	Introduction to Penile Cancer Shievon Smith & Michelle Greenwood, Uro-Oncology CNS Barts Health
	08:45hrs ~ 09:15hrs	Penile Cancer unmet needs Rob Cornes CNS Orchid Male Cancer Charity
	09:15hrs ~ 09:45hrs	Psychosexual Needs and Cancer Psychosexual CNS Lorraine Grover, Harley Street Clinic
	09:45hrs ~ 09:50hrs	Introduction for female sexual health and Cancer Shievon Smith & Michelle Greenwood, Uro-Oncology CNS Barts Health
	09:50hrs ~ 10:20hrs	Patient perspective of sex and cancer Anita Brown, Bladder Cancer Patient
	10:20hrs ~ 10:30hrs	Panel discussion with Q&A Michelle Greenwood, Shievon Smith & Anita Brown
UKONS would like to thank the Champions Shievon Smith and Michelle Greenwood for organising this session		
10:30hrs ~ 12:00hrs	<b>Notch AGM – all registered OF21 HCPs Welcome</b>	
	10:30hrs ~ 10:50hrs	Introduction - Overview of the past 12 months Dr Caroline Dobeson / Dr Mark Baxter
	10:50hrs ~ 11:10hrs	NOTCH Showcase: Clinical Features, Management & Outcomes of Patients with Thymic Epithelial Neoplasia: a UK Multi-Centre Series Dr Abigail Gault
	11:10hrs ~ 11:30hrs	NOTCH Showcase: Real-world Outcomes of Immune-related Adverse Events in 2125 Patients Managed with Immunotherapy: a UK Multi-Centre Series Dr Anna Olsson-Brown
	11:30hrs ~ 12:00hrs	Announcement of board positions for upcoming year Research Symposium – 2022 Future directions... Dr Caroline Dobeson Dr Mark Baxter

TIME	SUBJECT
10:30hrs ~ 11:30hrs	<b>BAYER PROSTATE SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
10:30hrs ~ 11:30hrs	<b>MERCK PFIZER ALLIANCE RENAL SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
<b>11:45hrs ~ 12:45hrs</b>	<b>NOVARTIS PLATINUM SPONSOR BREAST SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
12:00hrs ~ 12:55hrs	EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
13:00hrs ~ 13:05hrs	<b>UKOF OPENS ~ WELCOME &amp; INTRODUCTION – CHAIR: PROFESSOR RUTH PLUMMER</b>
13:05hrs ~ 14:00hrs	<b>OPENING KEYNOTE SPEAKER – PROFESSOR LINDA BAULD</b> Cancer prevention and Covid-19: How do we align communicable and non-communicable disease responses as part of Covid recovery?
14:00hrs ~ 14:25hrs	EXHIBITION & CHARITY CORNER (PLEASE VISIT THE VIRTUAL STANDS)

TIME	SUBJECT		
14:30hrs ~ 17:00hrs	<b>BREAST BREAKOUT – CHAIRS: DR MARINA PARTON &amp; DR MARK VERRILL</b>		
	14:30hrs ~ 14:35hrs	Welcome and introduction	<i>Dr Marina Parton &amp; Dr Mark Verrill</i>
	14:35hrs ~ 15:00hrs	NCRI update and roles of CSF	<i>Mr Stuart McIntosh</i>
	15:00hrs ~ 15:25hrs	Conference updates	<i>Dr Olga Oikonomidou</i>
	15:25hrs ~ 15:50hrs	Fast Forward	<i>Professor Murray Brunt</i>
	15:50hrs ~ 16:15hrs	A year on covid	<i>Ms Karen Verrill</i>
	16:15hrs ~ 16:40hrs	ESMO data	<i>Dr Suzette Delaloge</i>
	16:40hrs ~ 16:55hrs	Q+A	<i>All faculty</i>
	16:55hrs ~ 17:00hrs	Summary and closure	<i>Dr Marina Parton &amp; Dr Mark Verrill</i>
14:30hrs ~ 16:55hrs	<b>COLORECTAL BREAKOUT – CHAIR: DR VICKY COYLE</b>		
	14:30hrs ~ 14:35hrs	Welcome and introduction	<i>Dr Vicky Coyle</i>
	14:35hrs ~ 15:00hrs	Highlights of ASCO/ESMO	<i>Dr Lizzy Smyth</i>
	15:00hrs ~ 15:30hrs	Total neoadjuvant therapy for rectal cancer	<i>Dr Sean O’Cathail</i>
	15:30hrs ~ 16:00hrs	Systemic therapy for MSI-H CRC	<i>Dr Kai Keen Shiu</i>
	16:00hrs ~ 16:30hrs	Optimising MDM management for CRC survivors	<i>Professor Katherine Van Loon</i>
	16:30hrs ~ 16:50hrs	Q+A	<i>All faculty</i>
	16:50hrs ~ 16:55hrs	Summary and closure	<i>Dr Vicky Coyle</i>
14:30hrs ~ 17:00hrs	<b>GYNAECOLOGY – CHAIR: DR YVETTE DREW</b>		
	14:30hrs ~ 14:35hrs	Welcome and Introductions	<i>Dr Yvette Drew</i>
	14:35hrs ~ 15:05hrs	Targeting High Grade Serous Ovarian Cancer Beyond PARPi	<i>Dr Stephanie Lheureux</i>
	15:05hrs ~ 15:30hrs	Novel follow-up strategies in Gynaecological Cancers	<i>Dr Esther Moss</i>
	15:30hrs ~ 15:55hrs	Cervical cancer advances and current UK trial portfolio	<i>Dr Rebecca Bowen</i>
	15:55hrs ~ 16:15hrs	The challenges and future directions of surgical trials in gynaecological oncology	<i>Professor Christina Fotopoulou</i>
	16:15hrs ~ 16:30hrs	ESMO 2021 Gynae -the Professors round-up	<i>Professor Iain McNeish</i>
	16:30hrs ~ 16:50hrs	Panel Q and A session	<i>All speakers and Chair</i>
	16:50hrs ~ 17:00hrs	Summary and closing remarks	<i>Dr Yvette Drew</i>

TIME	SUBJECT		
14:30hrs ~ 16:45hrs	<b>HEAD &amp; NECK BREAKOUT – CHAIR (DR CHARLES KELLY)</b>		
	14:30hrs ~ 14:35hrs	Welcome and introduction	<i>Dr Charles Kelly</i>
	14:35hrs ~ 15:00hrs	The clinical consequences of HPV in H&N clinics in 10 years	<i>Dr Kate Cuschieri</i>
	15:00hrs ~ 15:25hrs	Reirradiation AND head and neck	<i>Dr Shahid Iqbal</i>
	15:25hrs ~ 15:50hrs	Where we will be in H&N surgery in ten years' time	<i>Professor Vinidh Paleri</i>
	15:50hrs ~ 16:20hrs	The next 10 years in H&N Radiotherapy	<i>Professor Paolo Bossi</i>
	16:20hrs ~ 16:40hrs	Q+A	<i>All faculty</i>
	16:40hrs ~ 16:45hrs	Summary and closure	<i>Dr Charles Kelly</i>
14:30hrs ~ 16:45hrs	<b>LIVER &amp; PANCREATIC BREAKOUT - CHAIRS: MS ANITA BALAKRISHNAN &amp; PROFESSOR DEREK O'REILLY</b>		
	14:30hrs ~ 14:35hrs	Welcome and introduction	<i>Ms Anita Balakrishnan &amp; Professor Derek O'Reilly</i>
	14:35hrs ~ 15:00hrs	Enriching the pool of patients with pancreatic cancer that benefit from chemotherapy, in particular clinical trials such as POLO that used this approach	<i>Professor Eileen M. O'Reilly</i>
	15:00hrs ~ 15:25hrs	Clinical trials in pancreatic cancer surgery	<i>Professor Chris Halloran</i>
	15:25hrs ~ 15:55hrs	Advance in the treatment of colorectal liver metastases	<i>Professor Jean Nicolas Vauthey</i>
	15:55hrs ~ 16:20hrs	Novel advances in the systemic and locoregional treatments for cholangiocarcinoma	<i>Dr Thankamma Ajith Kumar</i>
	16:20hrs ~ 16:45hrs	Summary and closure	<i>Ms Anita Balakrishnan &amp; Professor Derek O'Reilly</i>

TIME	SUBJECT
14:30hrs ~ 16:45hrs	<b>LUNG BREAKOUT – CHAIR: PROFESSOR SAMREEN AHMED</b>
	<i><b>The ever-changing landscape of early and advanced NSCLC</b></i>
14:30hrs ~ 14:35hrs	Welcome and introduction <i>Professor Samreen Ahmed</i>
14:35hrs ~ 14:50hrs	Update on advanced non-oncogene driven NSCLC: pivotal studies leading to current practice and then allude to perioperative treatment being the direction of travel with immunotherapy given adjuvantly <i>Dr Tom Newsom-Davis</i>
14:50hrs ~ 15:05hrs	Update on advanced oncogene driven NSCLC: : pivotal studies leading to current practice and then allude to perioperative treatment being the direction of travel with osimertinib given adjuvantly for potential cure: <i>Dr Riyaz Shah</i>
15:05hrs ~ 15:15hrs	Panel Q and A session <i>All speakers and Chair</i>
15:15hrs ~ 15:30hrs	The advantages and pitfalls of genomic testing in lung cancer: development of genomic hubs and their purpose, how is genomic testing being rolled out and when will NGS be available in lung cancer for the majority of the country. Concept of the test directory: <i>Dr Rachel Butler</i>
15:30hrs ~ 15:40hrs	Panel Q and A session <i>All speakers and Chair</i>
15:40hrs ~ 15:55hrs	Update on radiotherapy advances in NSCLC (all stages): present pivotal studies leading to current practice and some discussion of oligomets treatments and outcomes: <i>Dr Sridhar Thiagarajan</i>
15:55hrs ~ 16:15hrs	Perioperative therapies: A surgical perspective: surgical outcomes for patients receiving chemotherapy/immunotherapy/radiotherapy. Some discussion of stage 3 operability: <i>Mr Sridhar Rathinam</i>
16:15hrs ~ 16:40hrs	Panel Q and A session <i>All speakers and Chair</i>
16:40hrs ~ 16:45hrs	Summary and closure <i>Professor Samreen Ahmed</i>

TIME	SUBJECT
14:30hrs ~ 16:50hrs	<b>MELANOMA BREAKOUT – CHAIR: DR SAMRA TURAJLIC</b>
14:30hrs ~ 14:35hrs	Welcome and introduction <i>Dr Samra Turajlic</i>
14:40hrs ~ 15:05hrs	Where next for uveal melanoma? <i>Professor Richard Cavajal</i>
15:05hrs ~ 15:10hrs	Q&A <i>All</i>
15:10hrs ~ 15:35hrs	Will the margin literature still be relevant if patients with Stage 2 are getting CPIs? OR Should neoadjuvant CPI be SOC in melanoma <i>Dr Alexander van Akkooi</i>
15:35hrs ~ 15:40hrs	Q&A <i>All</i>
15:40hrs ~ 16:05hrs	Symptomatic brain metastases: curing the incurable? <i>Dr Kim Margolin</i>
16:05hrs ~ 16:10hrs	Q&A <i>All</i>
16:10hrs ~ 16:25hrs	ASCO/ESMO update <i>Professor James Larkin</i>
16:25hrs ~ 16:30hrs	Q&A <i>All</i>
16:30hrs ~ 16:45hrs	Panel discussion/debate <i>All Faculty</i>
16:45hrs ~ 16:50hrs	Wrap up & close <i>Dr Samra Turajlic</i>
14:30hrs ~ 16:50hrs	<b>PROSTATE BREAKOUT – CHAIR PROFESSOR NICK VAN AS</b>
14:30hrs ~ 14:35hrs	Welcome and introduction <i>Professor Nick Van As</i>
14:35hrs ~ 15:00hrs	MRI in PCa, when to use, how to scan, what to look for? <i>Dr Clare Allen</i>
15:00hrs ~ 15:30hrs	Metastasis directed therapy, when, how, what next? <i>Professor Piet Ost</i>
15:30hrs ~ 16:00hrs	Surgery in high risk and metastatic disease. Should we be doing it? <i>Professor Noel Clarke</i>
16:00hrs ~ 16:30hrs	Where to next fix systemic therapy in castrate sensitive PCa <i>Professor Christopher Sweeney</i>
16:30hrs ~ 16:45hrs	Panel Q+A <i>All faculty</i>
16:45hrs ~ 16:50hrs	Summary and closure <i>Professor Nick Van As</i>
16:45hrs ~ 17:20hrs	EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
17:30hrs ~ 18:45hrs	<b>THE BIG COVID CANCER/CANCER DISCUSSION – CHAIR PROFESOR DANIEL HOCHHAUSER</b> <b>Panel: <i>Dr Phil Hammond, Professor Linda Bauld &amp; Professor Peter Openshaw</i></b>



## DAY TWO – FRIDAY 22ND OCTOBER 2021

TIME	SUBJECT
08:00hrs ~ 08:45hrs	<b>JANSSEN-CILAG PROSTATE SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
08:00hrs ~ 08:45hrs	<b>BAYER PAN TUMOUR SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
08:00hrs ~ 09:10hrs	EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
<b>09:15hrs ~ 11:50hrs</b>	<b>ACUTE ONCOLOGY BREAKOUT - CHAIR: DR ERNIE MARSHALL</b>
	<p><i>The establishment of acute oncology services was first recommended in 2009 as an NHS requirement for all Hospital Trusts with an A&amp;E department. Since its inception, acute oncology has become widely established across the country, leading to improvements in safety and quality of unplanned cancer care. However, despite this progress, there remains distinct variation in access to specialist advice with many teams only able to deliver 5 day service. Traditional acute oncology has focussed largely on inpatient care and neutropenic sepsis at a time of rapidly changing cancer care and urgent care transformation.</i></p> <p><i>Acute Cancer care is much bigger than traditional acute oncology and is a major component of the wider urgent care system – a system that remains under intense pressure exacerbated by the COVID pandemic.</i></p> <p><i>Late presentation of new cancers, treatment complications and cancer progression in an aging and multi-morbid population will require a system response in which Oncology must work ever more closely with urgent care partners. Acute Cancer presentation and service redesign will demand ever greater oncology leadership and vision if sustainable change is to be achieved. This approach should include novel approaches to reduce late presentation, management pathways that support networked services, greater access for same day emergency care (SDEC) and a greater focus on acute cancer research.</i></p> <p><i>The UK Oncology Forum inaugural Acute Oncology session will aim to show case some of the AO innovation that is taking place and highlight the need to develop a future AO workforce and leadership structure that ensures Oncology is an effective collaborative partner to the wider urgent care system.</i></p>
09:15hrs ~ 09:20hrs	Welcome and Introduction <span style="float: right;"><i>Dr Ernie Marshall</i></span>
09:20hrs ~ 09:40hrs	Acute Oncology and Early Diagnosis: Oncology led Rapid Diagnostic Services <span style="float: right;"><i>Dr Saoirse Dolly</i></span>
09:40hrs ~ 10:00hrs	Digital Acute Oncology: lessons from COVID <span style="float: right;"><i>Dr Caroline Wilson</i></span>
10:00hrs ~ 10:30hrs	Cancer Centre Acute Oncology: The Acute Medicine Interface <span style="float: right;"><i>Dr Tim Cooksley</i></span>
10:30hrs ~ 11:00hrs	The Cancer Unit: Nurse Delivered AO in the real World <span style="float: right;"><i>Ms Naomi Clatworthy / Ms Christine Rhall</i></span>
11:00hrs ~ 11:20hrs	I-O Toxicity Update <span style="float: right;"><i>Dr Anna Olssen Brown</i></span>
11:20hrs ~ 11:40hrs	Acute Oncology Careers: A joint voice from RCR/RCP and UKONS <span style="float: right;"><i>Dr Robert Stuart</i></span>
11:40hrs ~ 11:50hrs	Q&A and wrap up <span style="float: right;"><i>All Faculty</i></span>



TIME	SUBJECT
09:15hrs ~ 11:20hrs	<b>BASO BREAKOUT - CHAIR: MR ZAED HAMADY</b>
	<i>Recent insight into surgical oncology practice</i>
09:15hrs ~ 09:20hrs	Welcome and introduction <i>Mr Zaed Hamady</i>
09:20hrs ~ 09:45hrs	Surgical Management of Neuroendocrine Tumours <i>Mr Tom Armstrong</i>
09:45hrs ~ 09:50hrs	Q&A <i>All</i>
09:50hrs ~ 10:15hrs	Liver transplantation for cancer, future trend? <i>Mr Raj Prasad</i>
10:15hrs ~ 10:20hrs	Q&A <i>All</i>
10:20hrs ~ 10:45hrs	Robotic HPB cancer surgery, the way for the future or optimistic <i>Mr Gabrielle Marangoni</i>
10:45hrs ~ 10:50hrs	Q+A <i>All</i>
10:50hrs ~ 11:15hrs	Panel discussion <i>Panel discussion</i>
11:15hrs ~ 11:20hrs	Summary and closure <i>Mr Zaed Hamady</i>
09:15hrs ~ 11:45hrs	<b>BRAIN METASTASES AND GLIOMAS BREAKOUT - CHAIR: DR CATHERINE MCBAIN</b>
	In this session, we will review advances in the management in primary and secondary brain tumours, with a particular focus on the role of steroids and the interplay with immunotherapy. The session will be cross-cutting, spanning the evidence base while interrogating when, why and how we use dexamethasone and how we can ensure we are achieving benefits while minimising complications. Using real-life case histories, we will discuss advances in the treatment of primary malignant gliomas and, taking melanoma as our example, interrogate all the options (neurosurgery, stereotactic radiotherapy, whole brain radiotherapy and systemic therapy) for brain metastases. We will describe how we can protect our patients from steroid-induced harm, focusing particularly on bone health and diabetes, and discuss the important recently released 2021 National Patient Safety Alert around dexamethasone. We will close by asking whether there are any viable alternatives to steroid use. The session will be interactive and will be of relevance to any health care professional who encounters patients with primary or secondary brain tumours in primary care, secondary care, acute oncology or tertiary centres.
09:15hrs ~ 09:20hrs	Welcome and introduction <i>Dr Catherine McBain</i>
09:20hrs ~ 09:45hrs	Primary brain tumours: current management and the truth about steroid requirements <i>Professor Susan Short</i>
09:45hrs ~ 10:10hrs	Immunotherapy in Neuro-Oncology <i>Professor Dr Michael Weller</i>
10:10hrs ~ 10:35hrs	Secondary brain tumours: multidisciplinary management <i>Professor Paul Lorigan</i>
10:35hrs ~ 10:55hrs	Minimising complications of steroid use <i>Dr Janhoong Ho</i>
10:55hrs ~ 11:10hrs	Alternatives to steroids – are there any? <i>Dr Gerben Borst</i>
11:10hrs ~ 11:40hrs	Review quiz and Q+A <i>All faculty</i>
11:40hrs ~ 11:45hrs	Summary and closure <i>Dr Catherine McBain</i>

TIME	SUBJECT
09:15hrs ~ 11:30hrs	<p data-bbox="371 193 1413 220"><b>MACMILLAN GP SESSION BREAKOUT - DAY – CHAIR: DR ANTHONY CUNLIFFE</b></p> <p data-bbox="371 236 1104 263"><b><i>‘Personalised care and cancer- it’s everyone’s business’</i></b></p> <p data-bbox="371 284 2105 534"><i>Ensuring that people living with cancer receive personalised care is everyone’s business, with touchpoints from the point of diagnosis, through to prehab, treatment decisions, acutely unwell episodes, good quality cancer care review conversations, needs assessments, gaining support from social prescribers and courageous end of life care conversations. The COVID-19 pandemic has notably impacted patient care over the past 12-18 months, with changes to ways of working, huge reductions in patients presenting with signs or symptoms of cancer and changes or delays to treatment plans due to infection risk. All of these changes have had an impact on the ability of health and care Professoessionals to continue to ensure the delivery of good quality personalised care for people living with cancer.</i></p> <p data-bbox="371 596 2105 847"><i>In this workshop, we’ll explore the impact of the pandemic on the delivery of personalised care for people living with cancer and will consider how we can sustain positive changes to ways of working and innovative adaptations to delivery of care developed through the pandemic, whilst ensuring that inequalities are not exacerbated as a result. This session will bring together a multi-Professoressional team to consider how we can build on the strengths of different Professoressionals involved in delivering care to people following a cancer diagnosis. Through the use of case studies, we’ll generate an interactive conversation based around the key times of need experienced by cancer patients to draw out what each individual can bring to achieving personalised care supported by evidence and insight throughout.</i></p> <p data-bbox="371 908 1285 935"><b><i>Speakers: Dr Anthony Cunliffe (Chair), Dr Ashling Lillis, Ms June Davis</i></b></p>

TIME	SUBJECT		
<b>09:15hrs ~ 11:45hrs</b>	<b>RADIOTHERAPY BREAKOUT - CHAIR FIONA MCDONALD</b>		
09:15hrs ~ 09:20hrs	Welcome and Introduction		<i>Dr Fiona McDonald</i>
09:20hrs ~ 09:55hrs	The future of hypo-fractionated treatments – What lessons can be learnt from FAST FORWARD?		<i>Professor Charlotte Coles</i>
09:55hrs ~ 10:25hrs	The future of the UK Proton Programme – Where are we in 2021 and what are future plans?		<i>Dr Romelie Rieu</i>
10:25hrs ~ 10:30hrs	Coffee break		
10:30hrs ~ 11:00hrs	The future of drug-radiation studies – Lessons learnt from developing CONCORD?		<i>Dr Alastair Greystoke</i>
11:00hrs ~ 11:30hrs	The future of UK SABR – Challenges of national rollout and ongoing research		<i>Dr John Conibear</i>
11:30hrs ~ 11:45hrs	Panel discussion		<i>All</i>
11:30hrs ~ 11:45hrs	Summary and close		<i>Dr Fiona McDonald</i>
<b>09:15hrs ~ 11:50hrs</b>	<b>RENAL &amp; BLADDER BREAKOUT - CHAIRS: PROFESSOR ALISON BIRTLE &amp; PROFESSOR PETER HOSKINS</b>		
	<b><i>'The Bladder/Renal Jigsaw : Putting the pieces together'</i></b>		
09:15hrs ~ 09:20hrs	Welcome and introduction		<i>Professor Alison Birtle &amp; Professor Peter Hoskins</i>
09:20hrs ~ 09:40hrs	Surgical areas of controversy in urothelial cancer		<i>Miss Jo Cresswell</i>
09:40hrs ~ 10:05hrs	What is needed in bladder/renal cancer from patient perspective		<i>Ms Shievon Smith</i>
10:05hrs ~ 10:25hrs	Metastatic and urothelial cancer. How has the world changed in 2021? Did practice change during covid-1		<i>Professor Syed Hussein</i>
10:25hrs ~ 10:45hrs	MRI in bladder cancer avoiding TURBT		<i>Professor Nicholas James</i>
10:45hrs ~ 11:00hrs	ESMO/ASCO/ASCO GU update		<i>Professor Syed Hussein</i>
11:00hrs ~ 11:15hrs	Imaging of urothelial cancers including TTCs of the kidney		<i>Dr Ben Taylor</i>
11:15hrs ~ 11:30hrs	Stereotactic and more!		<i>Dr Kate Fife</i>
11:30hrs ~ 11:45hrs	Panel discussion		<i>All</i>
11:45hrs ~ 11:50hrs	Summary and close		<i>Professor Alison Birtle &amp; Professor Peter Hoskins</i>



TIME	SUBJECT		
<b>09:15hrs ~ 11:35hrs</b>	<b>TREATING THE OLDER CANCER PATIENT BREAKOUT - CHAIR: PROFESSOR KWOK-LEUNG CHEUNG</b>		
	09:15hrs ~ 09:20hrs	Welcome and introduction	<i>Professor Kwok-Leung Cheung</i>
	09:20hrs ~ 09:40hrs	Prehabilitation – using hepatobiliary malignancy as an example	<i>Mr Nicola de' Liguori Carino</i>
	09:40hrs ~ 10:00hrs	ASCO updates	<i>Dr Antonella Brunello</i>
	10:00hrs ~ 10:20hrs	The impact of Covid-19 on older patients with cancer	<i>Dr Giuseppe Colloca</i>
	10:20hrs ~ 10:35hrs	Q+A	<i>All faculty</i>
	10:35hrs ~ 10:45hrs	BREAK	
	10:45hrs ~ 11:15hrs	Difficult and challenging cases – MDT discussion	<i>Dr Lisa Rodgers and Dr Anthea Cree (co-leads) and all faculty</i>
	11:15hrs ~ 11:30hrs	Q+A	<i>All faculty</i>
	11:30hrs ~ 11:35hrs	Summary and closure	<i>Professor Kwok-Leung Cheung</i>
<b>09:15hrs ~ 11:30hrs</b>	<b>UKOMIC BREAKOUT - CHAIR: DR CHARLES KELLY</b>		
	09:15hrs ~ 09:20hrs	Welcome and introduction	<i>Dr Charles Kelly</i>
	09:20hrs ~ 09:50hrs	Oral health in head and neck cancer patients	<i>Dr Gerry Mckenna &amp; Dr Ciaran Moore</i>
	09:50hrs ~ 09:55hrs	Q&A	<i>All faculty</i>
	09:55hrs ~ 10:25hrs	Nordic Team presenting guidance on oral health after cancer and cancer treatments	<i>Ms Elisabeth Wallhult, Ms Lea Brandt Kritensen &amp; Ms Ann-Mari Berthelsen</i>
	10:25hrs ~ 10:30hrs	Q&A	<i>All faculty</i>
	10:30hrs ~ 10:55hrs	TBC	<i>Dr Barry Quinn</i>
	10:55hrs ~ 11:00hrs	Q&A	<i>All faculty</i>
	11:00hrs ~ 11:20hrs	Panel discussion	<i>All faculty</i>
	11:20hrs ~ 11:30hrs	Summary & close	<i>Dr Charles Kelly</i>

TIME	SUBJECT	
09:15hrs ~ 11:40hrs	<b>UKONS BREAKOUT – CHAIR: MS TRACY WILSON</b>	
	<p><b>Title-</b> Prehabilitation and beyond: Preparing for the future</p> <p><b>Aims-</b></p> <ul style="list-style-type: none"> <li>• Identify the rationale for prehabilitation and rehabilitation</li> <li>• Identify workforce opportunities</li> <li>• Demonstrate an evidence base for service development</li> </ul> <p><b>Sessions-</b></p> <ol style="list-style-type: none"> <li>1. Behaviour change- universal interventions</li> <li>2. Non-specialist workforce- utilising existing workforce</li> <li>3. Specialist interventions- developing specialist services</li> <li>4. Building a business case- how to pitch your argument!</li> <li>5. Panel discussion</li> </ol>	
09:15hrs ~ 09:20hrs	Introduction - why think about prehab? What's it all about?	<i>Ms Tracy Wilson</i>
09:20hrs ~ 09:45hrs	Behaviour change in practice - <b>more than meets the eye. The SafeFit model</b>	<i>Ms Judit Varkonyi-Sepp</i>
09:45hrs ~ 10:10hrs	Non-specialist workforce - <b>example of how non-specialist prehab practitioners incorporated into their practice</b>	<i>Ms Jo McNamara / Ms Hazel Pennington</i>
10:10hrs ~ 10:35hrs	Specialist interventions - <b>when you need that bit more. Case study on setting up the specialist prehab/rehab service in Sheffield</b>	<i>Mr Liam Humphreys</i>
10:35hrs ~ 11:00hrs	Building a business case - <b>what do you need to make an impact? How can you persuade others to make a system change?</b>	<i>Mr Jason Tong / Ms Shana Hall / Ms Leah Cox</i>
11:00hrs ~ 11:30hrs	Panel discussion	<i>All</i>
11:30hrs ~ 11:40hrs	Closing remarks	<i>Ms Tracy Wilson</i>

TIME	SUBJECT
09:15hrs ~ 11:40hrs	<b>UPPER GI BREAKOUT - CHAIRS: PROFESSOR RUSSELL PETTY &amp; DR JANET GRAHAM</b>
	<i>The last 12 months have provided us with a series of positive trials in gastroesophageal cancer providing new treatment options for our patients. This session will provide updates from these practice changing studies reported in 2021, straight from the chief investigators themselves and combine this with a real-world perspective of the challenges of managing gastroesophageal cancer patients in practice. We will discuss how the latest trial outcomes can be applied to make optimal treatment choices for individual patients in the advanced and early-stage settings, for systemic, radiotherapy and surgical treatment.</i>
09:15hrs – 09:20hrs	Welcome and introduction <i>Professor Russell Petty &amp; Dr Janet Graham</i>
09:20hrs ~ 09:40hrs	Decision making in peri-operative treatment of gastroesophageal cancer - what have we learnt from the neo-Aegis Trial <i>Professor John Reynolds</i>
09:40hrs ~ 09:55hrs	Defining the optimal role for checkpoint inhibitors in the perioperative treatment of gastroesophageal cancer <i>Dr Lizzy Smyth</i>
09:55hrs ~ 10:15hrs	Optimising the systemic treatment of older and frailer patients with advanced gastroesophageal cancer <i>Professor Matt Seymour</i>
10:15hrs ~ 10:35hrs	Checkmate 648 and the emerging role for Immunotherapy in Advanced Squamous cCII carcinoma Oesophagus <i>Dr Ian Chau</i>
10:35hrs ~ 11:05hrs	The state the art treatment of advanced gastroesophageal adenocarcinomas (including ASCO and ESMO updates) <i>Dr Yelena Janjigian</i>
11:05hrs ~ 11:30hrs	Q+A <i>All Faculty</i>
11:25hrs ~ 11:40hrs	Summary and closure <i>Professor Russell Petty &amp; Dr Janet Graham</i>
11:30hrs ~ 11:55hrs	EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
12:00hrs ~ 13:00hrs	<b>CLOSING KEYNOTE SPEAKER – PROFESSOR SAM JANES ~ UKOF CLOSES</b>
13:00hrs ~ 14:00hrs	EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
13:15hrs ~ 14:00hrs	<b>PIERRE FABRE MELANOMA SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
13:15hrs ~ 14:00hrs	<b>PIERRE FABRE CRC SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
13:15hrs ~ 14:00hrs	<b>SEAGEN – BREAST SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>

## Secretariat

Athena Meetings & Events

AXIS, Jordangate House

Jordangate

Macclesfield

England

SK10 1EQ

## Contact Details

Sharon Poole [sharon@athenameetings.com](mailto:sharon@athenameetings.com)

Lisa Young [lisa@athenameetings.com](mailto:lisa@athenameetings.com)

Jak Poole [jak@athenameetings.com](mailto:jak@athenameetings.com)